Mr. Adams joined Sepracor in March 2007 as President and Chief Operating Officer and, in May 2007, became President and Chief Executive Officer of the company. Most recently, Mr. Adams was with Kos Pharmaceuticals, Inc., where he served as President and Chief Operating Officer from April 2001, prior to becoming President and Chief Executive Officer in January 2002. In December 2006, Mr. Adams was instrumental in the sale of Kos to Abbott Laboratories. Having spent the majority of his career in the pharmaceutical industry, Mr. Adams has extensive senior and general management experience with a broad background encompassing research and development, sales, marketing, international and national product management and business development. Mr. Adams served as President and Chief Executive Officer of Novartis-UK from 1999 until his tenure began at Kos. For the previous seven years, Mr. Adams was with SmithKline Beecham Pharmaceuticals, last serving as President and CEO of the company's Canadian subsidiaries. Previous assignments at SmithKline Beecham included Vice President and Director of Worldwide Marketing in the U.S., and Director and Vice President of Sales and Marketing in the United Kingdom.

Mr. Adams began his career at ICI Pharmaceuticals, where he rose from research laboratory assistant to Director of Sales and Marketing. During his career, he has worked in most countries of the world and has experience in most primary care, specialist and biological therapeutic areas. In addition, he has been instrumental in a number of major global and national product launches including Paxil^®, Famvir^®, Coreg^®, Diovan^®, Tenormin^® and Zestril^®. He is a graduate of Manchester University in the United Kingdom with a Bachelor of Science degree.

Mr. Adams serves as a board member of PhRMA (Pharmaceutical Research and Manufacturer of America) and Amylin Pharmaceuticals.